Propensity score methods for confounding control in nonexperimental research

Circulation: Cardiovascular Quality and Outcomes

Volumn 6, Issue 5, 2013, Pages 604-611

  Brookhart, M Alan ^a,b   Wyss, Richard ^a   Layton, J Bradley ^a,b   Stürmer, Til ^a  

^a IL   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Epidemiologic methods; Propensity score

Indexed keywords

ARTICLE; HAZARD RATIO; HUMAN; LOGISTIC REGRESSION ANALYSIS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROBABILITY; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; SAMPLE SIZE;

EPIDEMIOLOGIC METHODS; PROPENSITY SCORE;

ANGIOEDEMA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CONFOUNDING FACTORS (EPIDEMIOLOGY); DATA INTERPRETATION, STATISTICAL; DATA MINING; HUMANS; MODELS, STATISTICAL; PROPENSITY SCORE; REPRODUCIBILITY OF RESULTS; RISK FACTORS;

EID: 84884469577     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.113.000359     Document Type: Article

References (44)

1. Brookhart MA, Stürmer T, Glynn RJ, Rassen J, Schneeweiss S. Confounding control in healthcare database research: challenges and potential approaches. Med Care. 2010;48(6 Suppl):S114-S120.
2. Walker AM. Confounding by indication. Epidemiology. 1996;7:335-336.
3. Kramer MS, Wilkins R, Goulet L, Séguin L, Lydon J, Kahn SR, McNamara H, Dassa C, Dahhou M, Masse A, Miner L, Asselin G, Gauthier H, Ghanem A, Benjamin A, Platt RW; Montreal Prematurity Study Group. Investigating socio-economic disparities in preterm birth: evidence for selective study participation and selection bias. Paediatr Perinat Epidemiol. 2009;23:301-309.
4. Glynn RJ, Schneeweiss S, Wang PS, Levin R, Avorn J. Selective prescribing led to overestimation of the benefits of lipid-lowering drugs. J Clin Epidemiol. 2006;59:819-828.
5. Glynn RJ, Knight EL, Levin R, Avorn J. Paradoxical relations of drug treatment with mortality in older persons. Epidemiology. 2001;12:682-689.
6. Winkelmayer WC, Levin R, Setoguchi S. Associations of kidney function with cardiovascular medication use after myocardial infarction. Clin J Am Soc Nephrol. 2008;3:1415-1422.
7. Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, Johnson JA. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006;333:15.
8. Brookhart MA, Patrick AR, Dormuth C, Avorn J, Shrank W, Cadarette SM, Solomon DH. Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol. 2007;166:348-354.
9. Dormuth CR, Patrick AR, Shrank WH, Wright JM, Glynn RJ, Sutherland J, Brookhart MA. Statin adherence and risk of accidents: a cautionary tale. Circulation. 2009;119:2051-2057.
10. Cepeda MS, Boston R, Farrar JT, Strom BL. Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. Am J Epidemiol. 2003;158:280-287.
11. Rosenbaum P, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41-55.
12. Leenen FH, Nwachuku CE, Black HR, Cushman WC, Davis BR, Simpson LM, Alderman MH, Atlas SA, Basile JN, Cuyjet AB, Dart R, Felicetta JV, Grimm RH, Haywood LJ, Jafri SZ, Proschan MA, Thadani U, Whelton PK, Wright JT; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2006;48:374-384.
13. Makani H, Messerli FH, Romero J, Wever-Pinzon O, Korniyenko A, Berrios RS, Bangalore S. Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors. Am J Cardiol. 2012;110:383-391.
14. Piller LB, Ford CE, Davis BR, Nwachuku C, Black HR, Oparil S, Retta TM, Probstfield JL; ALLHAT Collaborative Research Group. Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich). 2006;8:649-656; quiz 657.
15. Stojiljkovic L. Renin-angiotensin system inhibitors and angioedema: anesthetic implications. Curr Opin Anaesthesiol. 2012;25:356-362.
16. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11:550-560.
17. Sato T, Matsuyama Y. Marginal structural models as a tool for standardization. Epidemiology. 2003;14:680-686.
18. Stürmer T, Rothman KJ, Glynn RJ. Insights into different results from different causal contrasts in the presence of effect-measure modification. Pharmacoepidemiol Drug Saf. 2006;15:698-709.
19. Guo S, Fraser MW. Propensity Score Analysis: Statistical Methods and Applications. Thousand Oaks, CA: SAGE Publications; 2010.
20. Kurth T, Walker AM, Glynn RJ, Chan KA, Gaziano JM, Berger K, Robins JM. Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol. 2006;163:262-270.
21. Cole SR, Hernán MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol. 2008;168:656-664.
22. Cole SR, Hernán MA, Robins JM, Anastos K, Chmiel J, Detels R, Ervin C, Feldman J, Greenblatt R, Kingsley L, Lai S, Young M, Cohen M, Muñoz A. Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol. 2003;158:687-694.
23. Lunceford JK, Davidian M. Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. Stat Med. 2004;23:2937-2960.
24. Funk MJ, Westreich D, Wiesen C, Stürmer T, Brookhart MA, Davidian M. Doubly robust estimation of causal effects. Am J Epidemiol. 2011;173:761-767.
25. Bang H, Robins JM. Doubly robust estimation in missing data and causal inference models. Biometrics. 2005;61:962-973.
26. Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Stürmer T. Variable selection for propensity score models. Am J Epidemiol. 2006;163:1149-1156.
27. Patrick AR, Schneeweiss S, Brookhart MA, Glynn RJ, Rothman KJ, Avorn J, Stürmer T. The implications of propensity score variable selection strategies in pharmacoepidemiology: an empirical illustration. Pharmacoepidemiol Drug Saf. 2011;20:551-559.
28. Stürmer T, Joshi M, Glynn RJ, Avorn J, Rothman KJ, Schneeweiss S. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol. 2006;59:437-447.
29. McCaffrey DF, Ridgeway G, Morral AR. Propensity score estimation with boosted regression for evaluating causal effects in observational studies. Psychol Methods. 2004;9:403-425.
30. Setoguchi S, Schneeweiss S, Brookhart MA, Glynn RJ, Cook EF. Evaluating uses of data mining techniques in propensity score estimation: a simulation study. Pharmacoepidemiol Drug Saf. 2008; 17:546-555.
31. Ellis AR, Dusetzina SB, Hansen RA, Gaynes BN, Farley JF, Stürmer T. Confounding control in a nonexperimental study of STAR*D data: logistic regression balanced covariates better than boosted CART. Ann Epidemiol. 2013;23:204-209.
32. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127(8 pt 2):757-763.
33. Johannes CB, Koro CE, Quinn SG, Cutone JA, Seeger JD. The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy. Pharmacoepidemiol Drug Saf. 2007;16:504-512.
34. Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009;20:512-522.
35. Bhattacharya J, Vogt WB. Do instrumental variables belong in propensity scores? NBER Work Pap Ser. 2007. http://www.nber.org/papers/t0343. Accessed September 5, 2013.
36. Myers JA, Rassen JA, Gagne JJ, Huybrechts KF, Schneeweiss S, Rothman KJ, Joffe MM, Glynn RJ. Effects of adjusting for instrumental variables on bias and precision of effect estimates. Am J Epidemiol. 2011;174:1213-1222.
37. Greenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research. Epidemiology. 1999;10:37-48.
38. Stürmer T, Rothman KJ, Avorn J, Glynn RJ. Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution-a simulation study. Am J Epidemiol. 2010;172:843-854.
39. Schisterman EF, Cole SR, Platt RW. Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology. 2009;20:488-495.
40. Lunt M, Solomon D, Rothman K, Glynn R, Hyrich K, Symmons DP, Stürmer T; British Society for Rheumatology Biologics Register; British Society for Rheumatology Biologics Register Control Centre Consortium. Different methods of balancing covariates leading to different effect estimates in the presence of effect modification. Am J Epidemiol. 2009; 169:909-917.
41. Brown NJ, Ray WA, Snowden M, Griffin MR. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther. 1996;60:8-13.
42. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2008;167:492-499.
43. Hernán MA, Hernández-Díaz S, Robins JM. A structural approach to selection bias. Epidemiology. 2004;15:615-625.
44. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158:915-920.